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A novel class of small-molecule inhibitors of MDM2ep53 interaction with a (E)-3-benzylideneindolin-2-
one scaffold was identiﬁed using an integrated virtual screening strategy that combined both pharma-
cophore- and structure-based approaches. The hit optimisation identiﬁed several compounds with more
potent activity than the hit compound and the positive drug nutlin-3a, especially compound 1b, which
exhibited both the highest binding afﬁnity to MDM2 (Ki ¼ 0.093 mM) and the most potent anti-
proliferative activity against HCT116 (wild type p53) cells (GI50 ¼ 13.42 mM). Additionally, 1b dose-
dependently inhibited tumour growth in BALB/c mice bearing CT26 colon carcinoma, with no visible
sign of toxicity. In summary, compound 1b represents a novel and promising lead structure for the
development of anticancer drugs as MDM2ep53 interaction disruptors.
 2014 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
The tumour suppressor protein p53 plays a pivotal role in DNA
repair, cell cycle regulation and apoptosis [1,2]. Moreover, this
protein is an attractive anticancer therapeutic target because it can
be functionally activated to eradicate tumour. It has been estab-
lished that the p53 protein is mutated or deleted in half of human
cancers. In the remaining cases, p53 retains its wild type form, but
its activity is inhibited by the human murine double minute 2
(MDM2, also known as HDM2) oncoprotein via the following
mechanisms: a) binding to the p53 transactivation domain to
inhibit its transcriptional activity, b) exporting p53 out of the nu-
cleus, and c) promoting proteasome-mediated degradation of p53
[3]. Consequently, blocking the MDM2ep53 interaction to reac-
tivate p53 is a promising anticancer therapeutic strategy.
One successful approach for targeting proteineprotein in-
teractions (PPIs) is the rational design of small-molecules that
mimic the interaction of a few key residues (i.e., hot spots) at the
proteineprotein interface [4]. Unlike common PPIs, in which the
interface is large, shallow and nondescript [5], the MDM2-p53
interface consists of a cluster of narrow and deep hydrophobicy. Ji), l-z-r@263.net (Z.-r. Li).
r Masson SAS. This is an open acceclefts that could be targeted by small-molecule inhibitors. Muta-
tional analysis and alanine scanning of p53 peptides revealed that
the Phe19, Trp23 and Leu26 residues (hot spots) play an important
role in the interaction between p53 and MDM2 (Fig. 1) [6]. Hence,
these residues could be used as a template to design small-
molecule inhibitors. To date, there are over 20 different chemo-
types that have been shown to antagonise the MDM2ep53 inter-
action, including nutlins [7], benzodiazepinediones [8],
isoindolinones [9], chalcones [10], piperidinones [11], pyrrolidones
[12], pyrrolopyrimidines [13], spiro-oxindoles [14], and chrome-
notriazolopyrimidine [15], xanthones [16]. Among these, the nut-
lins, spiro-oxindoles (MI derivatives), and piperidinones (AM-8553)
have shown the most potential for development as clinical agents
to treat cancer (Fig. 1). Although these compounds share different
scaffold structures, they all inhibit the MDM2ep53 interaction by
mimicking the three hot spots residues of p53 (Fig. 1).
The nutlins were identiﬁed as the ﬁrst class of potent, non-
peptide, speciﬁc inhibitors of the MDM2ep53 interaction by high
throughput screening [7]. One of nutlin derivatives, nutlin-3a,
binds with high afﬁnity to MDM2, and it is orally active with no
visible sign of toxicity inmousemodels of human cancer containing
wild-type p53 [7,17]. One nutlin derivative, RO5045337, has already
entered phase I clinical trials [18]. Using a computational structure-
based de novo design strategy, Wang’s group discovered a new class
of inhibitors of the MDM2ep53 interaction, spiro-oxindoles [14].ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. a: The three hot spots residues involved in the MDM2ep53 interaction (PDB ID: 1YCR; the ﬁgure was generated using PyMol). b: The chemical structures of three main
inhibitors of the MDM2ep53 interaction and their modes of binding to MDM2.
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potent inhibitory activity (Ki ¼ 13.2 nM) and superior pharmaco-
kinetics (PK) proﬁles (oral bioavailability F ¼ 65%) [19]. Compound
MI-773, which was derived from this scaffold, has also entered
phase I clinical trials [18]. Recently, another promising inhibitor,
AM-8553, containing a piperidinone scaffold was designed using a
structure-based de novo strategy. This compound was reported to
have potent activity both in vitro and vivo, along with an oral
bioavailability of 100% in rats [11].
In summary, the interaction betweenMDM2 and p53 represents
a promising target for the development of novel anticancer drugs
that could be targeted by small-molecule inhibitors. To date,
although over 20 small-molecule inhibitors with a diversity array
scaffolds have been discovered, around 6 candidate compounds
with potent inhibitory activity and superior PK proﬁles have
entered clinical development [18]. It would therefore be highly
desirable to discover a novel small-molecule inhibitor with potent
activity and an improved ADMET proﬁle.
In this study, we sought to discover novel small-molecule in-
hibitors of the MDM2ep53 interaction with potent afﬁnity. We
identiﬁed a novel class of MDM2-p53 inhibitors with a 3-
benzylidene-indolin-2-one scaffold by combining both pharmaco-
phore- and structure-basedmethods as a virtual screening strategy.
Hit optimisation was also conducted, and the preliminary struc-
tureeactivity relationships were assessed. Additionally, a com-
pound with relatively potent activity in vitrowas chosen to further
assay its antitumour activity in vivo.
2. Results and discussion
2.1. Virtual screening and hit identiﬁcation
Computer-aided drug design (CADD) plays an indispensable role
both in the discovery and optimisation of hit/lead compounds.
Currently, two computational 3D database-screening approaches
are available, pharmacophore- and structure-based approaches.The primary advantages of the pharmacophore-based method are
its high screening speed and rapid elimination of compounds
without critical binding elements. However, this method suffers
from a high false positive rate because it does not consider the
receptor. Alternatively, the structure-based method (docking) can
quantitatively assess the binding afﬁnity of a compound for its
target protein, but this process is rather time-consuming. Clearly,
these two methods complement each other in terms of screening
speed and accuracy of screening results; hence, combining these
two complementary approaches is a valid screening strategy
[20,21].
In this study, we employed an integrated screening strategy
combining pharmacophore- and structure-based methods. It is
widely accepted that the interaction between inhibitors andMDM2
primarily involve three hydrophobic pockets (Phe19, Trp23 and
Leu26). Based on this information, a simple pharmacophore model
was constructedmanually in Discovery studio 3.0 (DS 3.0). First, the
crystal structure of a known inhibitor (Pip-1, a derivative of the
piperidinones) complexed with MDM2 (PDB ID: 2LZG) was
employed as reference, and four hydrophobic features (Fig. 2, blue
(in the web version) spheres) were constructed manually based on
its interaction with MDM2. Additionally, to avoid receptor in-
teractions, the a-C atoms of the amino acids within 5A of the ligand
were selected and marked as exclusion volumes (Fig. 2, grey
spheres).
To validate the generated pharmacophore hypotheses, a test set
consisting of 16 active compounds and 48 inactive compounds was
collected. The active compounds were all extracted from the PDB
database and the reported literature, and the inactive compounds,
also known as the decoy set, were derived according to Wallach’s
method [22]. The compounds in the decoy set had to satisfy the
following constraints with respect to the reference drug (Pip-1): a)
molecular weight of 40 Da; b) the exact same number of rota-
tional bonds, hydrogen bond donors (HBDs), and hydrogen bond
acceptors (HBAs); c) a CLogP of 1.0 (ALogP was used here); and d)
a Tanimoto coefﬁcient of less than 0.9. The “Screen library” and
Fig. 2. a: The manually constructed pharmacophore model with exclusion volumes. b: The ROC curve for the generated pharmacophore.
Fig. 3. a: Chemical structure of compound 4b. b: Inhibitory activity of compound 4b
against the MDM2ep53 interaction in MCF7 cells (co-immunoprecipitation
experiment).
Fig. 4. The proposed binding mode of compound 4b to MDM2 (generated using
PyMol).
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inhibitors were enriched from the test set; however, 12 non-
inhibitors were also retrieved (false positives). The area under the
ROC curve was 0.798, and the ROC evaluation was “fair”. These
results indicate that this pharmacophorewas sufﬁciently good to be
used as a 3D query to retrieve potential hit compounds.
The validated pharmacophore hypothesis was then used as a 3D
query for retrieving potential inhibitors from S406-SETA, S406-
SETB, Maybridge and the NCI database in Catalyst. The “Screen li-
brary” module in DS 3.0 was used. The “Conformation generation”
was set to “fast”, and the other parameters were set as default. The
identiﬁed compounds were further ﬁltered by the Lipinski’s rule of
ﬁve. Lastly, a total of approximately 6000 compounds were
retrieved for further docking studies (structure-based approach).
2.2. Docking study and biological assay in vitro
To further verify the compounds identiﬁed by pharmacophore
mapping, the 6000 retrieved compounds were docked into the p53
binding pockets of MDM2. The protein structure PDB ID 3LBL was
chosen as the reference receptor because its ligand had high
binding afﬁnity (Ki ¼ 32 nM) and high resolution (1.6 A). Docking
was performed using sybyl 7.3, and the Surﬂex-Dockmodule (SFXC)
was employed. All the parameters were set as default. After dock-
ing, the potential hits were cherry-picked for synthesis and bio-
logical assays in vitro based on their docking scores, scaffold
diversity, synthesizability, and most importantly, their docking
poses. Based on their docking poses predicted by SFXC, we per-
formed a visual inspection to conﬁrm that all the chosen potential
hits mimicked the three hot spot residues of p53 and occupied the
three main hydrophobic pockets of MDM2. Ultimately, 10 com-
pounds with diversity of scaffolds (Please refer to Supplementary
data) were selected for synthesis, and each was subjected to ﬂuo-
rescence polarisation assay to validate their inhibitory activity
against the MDM2ep53 interaction; nutlin-3a, which is one of the
most potent inhibitors of the MDM2ep53 interaction, was used as
the positive control.
Fortunately, one compound (4b, Fig. 3) showed relatively high
binding afﬁnity (Ki ¼ 0.23 mM) to MDM2 with (E)-3-
benzylideneindolin-2-one scaffold, and hence compound 4b was
identiﬁed as hit compound for further optimisation.
2.3. Design
To gain a better understanding of the interaction between
compound 4b and MDM2, we proposed a possible binding mode of
compound 4b and MDM2 based on its docking pose generated byAutodock, which is one of the most widely used docking pro-
grammes [23]. As shown in Fig. 4, benzene ring A and the propoxyl
groups on the 2- and 4-position (R3 & R5) of benzene ring B
occupied the hydrophobic pockets of Phe19, Trp23, and Leu26,
respectively. By analysing the bindingmodes of known inhibitors to
MDM2, we concluded that hydrophobic aromatic rings with
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tionally, given that the biphenyl scaffold is a privileged structure in
medicinal chemistry, we designed and synthesised a series of
compounds with phenyl substituted at the 2-position (R3) of ben-
zene ring B (1fe3f, 1h and 2h). Given that there were no sub-
stituents on the ring A, which likely made it vulnerable to
metabolism, compounds with substituents on ring A were syn-
thesised to make them metabolically stable and to investigate the
SAR on ring A. Halogens play a vital role in drug development, and
around 25% of the “top 200 brand name drugs by retail dollar in
2009” possesses halogens in their chemical structures. Additionally,
halogens show a potential ability to form halogen bonding with the
target. Consequently, the substituents chosen here were primarily
halogens (F and Cl) [24]. In addition, other compounds with various
substituents on benzene ring B (1be7b) were synthesised to assay
their binding afﬁnity to MDM2 using ﬂuorescence polarisation
assay.Fig. 5. Scheme of compound 1b with atom-numbering. The displacement parameters
are shown at the 30% probability level.2.4. Chemistry
As shown in Scheme 1, compound 4b and several derivatives
were synthesised. 2, 4-Dihydroxybenzaldehyde was used as the
starting material, and it was used in reactions with alkyl iodide to
yield compounds 1ae3a. These compounds were then condensed
with substituted indolin-2-one in ethanol under reﬂux using
piperidine as the base to afford the target compounds 1be7b.
The conﬁguration of the double bond in compounds 1be7bwas
assigned to E based on the results of the NOESY experiment. In this
experiment, a strong interaction between the hydrogen atom at the
4-position of ring A and the 2-position (R3) of ring B was observed,
and there was no interaction between the hydrogen atom on the
double bond and the hydrogen bond at the 4-position (R5) of ring A
(Scheme 1). Additionally, the X-ray single crystal structure of
compound 1bwas determined. As shown in Fig. 5, benzene rings A
and B were on the same side of the double bond, as expected.
Based on the binding mode of compound 4b to MDM2, a series
of derivatives with substituted phenyl at the 2-position (R3) of
benzene ring B were designed and synthesised. As depicted in
Scheme 2, substituted bromobenzene was coupled with bis(pina-
colato)diboron using tetrakis(triphenylphosphine)palladium as the
catalyst to produce compounds 1d and 2d. Under the conditions of
the Suzuki coupling reaction, compound 2d was reacted with
substituted 2-bromobenzaldehyde to yield compounds 1e and 2e,
which were further condensed with the substituted indolin-2-one
to afford the target compounds 1f-3f. However, when compoundScheme 1. Conditions and reagents: a) K2CO3, DMF, alkyl iodide, 60 C, 80e90%; b)
EtOH, piperidine, substituted indolin-2-one, reﬂux, 4 h, 80e90%.1d was coupled with the substituted 2-bromobenzaldehyde, no
trace of the corresponding target compounds was detected. We
therefore adjusted the reaction sequence. The substituted indolin-
2-one was ﬁrst condensed with 2-bromo-4-methoxybenzaldehyde
to produce compounds 1g and 2g, which were then coupled with
compound 1d under the conditions of the Suzuki coupling reaction
to afford the desired compounds. The conﬁguration of the double
bond of all the target compounds was conﬁrmed using the NOESY
experiment (Scheme 3).
2.5. MDM2 binding afﬁnity and structure activity relationships
The MDM2 binding afﬁnity of all the target compounds was
determined by ﬂuorescence polarisation assay. Nutlin-3a was used
as positive control to validate our assay, and the results were
summarised in Table 1.
As shown in Table 1, our assay was validated by the positive
control nutlin-3a, of which the Ki value (0.11 mM) was comparable
to the reported one (0.23 mM) [12]. In general, all of the synthesised
compounds showed high binding afﬁnity to MDM2, and this was
especially true for compounds 1b, 2b, 1f, 2f, 1h and 2h, which
exhibited superior or comparable activity to nutlin-3a. Unexpect-
edly, of all the synthesised compounds,1b showed the most potent
activity with a Ki value of 0.093 mM. This effect was not consistent
with the binding mode of 4b to MDM2 given that the Trp23 pocket
was less occupied in the presence of the methoxyl group compared
to its n-propoxyl substituted counterpart. The only reasonable
explanation is that compound 1b displayed a distinct bindingmode
to MDM2. As depicted in Fig. 6, a binding mode of compound 1b to
MDM2 was proposed based on its docking pose generated by
Autodock. A hydrogen bond was formed between His-96 of MDM2
Scheme 2. Conditions and reagents: a) Bis(pinacolato)diboron, KOAc, Pd(PPh3)4,
DMSO, 85 C, 4 h, N2, 75%; b) substituted 2-bromobenzaldehyde, Ce2CO3, Pd(PPh3)4,
N2, 120 C, 4 h, 70e80%; c) EtOH, piperidine, substituted indolin-2-one, reﬂux, 4 h, 80e
90%.
Scheme 3. Conditions and reagents: a) EtOH, piperidine, aldehyde, reﬂux, 3 h, 80e
90%; b) 1d, Ce2CO3, Pd(PPh3)4, N2, 120 C, 4 h, 70e80%.
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occupied the Phe19 and Trp23 pocket, respectively. The Leu26
pocket was less occupied.
In terms of the structureeactivity relationships, introduction of
the chloro group at 5-position (R2) of the indolin-2-one ring (2b)
had little inﬂuence on the binding afﬁnity compared to 1b. How-
ever, decreased inhibitory activity was observed when replacing
the H atom at 6-position (R1) of the indolin-2-one (1b) with a ﬂuoro
group (3b). Replacing the methoxyl group at 2-position (R3) of B
ring (2b) with a bromine atom (1g) also slightly decreased the
activity. In the case of compound 4b, both introduction of a chloro
substituent at 5 or 6-position (R2 & R1) and substitution the iso-
propoxyl group for the n-propoxyl group did not alter the binding
afﬁnity. When the n-propoxyl groups at the 2- and 4-positon (R3 &
R5) of the B ring were replaced by 4-chloro phenyl or 4-cyano
phenyl substituents and a methoxyl group, respectively, we
observed a slight increase in the binding afﬁnity to MDM2, which
was in consistence with the binding mode of compound 4b to
MDM2. Migration of the methoxyl group from 4-position (R5) to 3-
position (R4) of ring B (3f) showed little inﬂuence on the binding
afﬁnity.
The binding mode of compound 2h to MDM2was also proposed
based on its docking pose generated by Autodock. As depicted in
Fig. 7, compound 2h shared a similar binding mode to that of
compound 4b. As expected, the 4-chloro phenyl group occupied the
Trp-23 hydrophobic pocket, but the methoxyl group left the Phe-19
pocket less occupied, and this may explain why compounds with
substituted phenyl at ring B only showed slight increase in binding
afﬁnity compared to their propoxyl substituted counterparts.2.6. In-vitro antiproliferative activity
The synthesised compounds were further assayed for their
antiproliferative activity in human colon cancer (HCT116 with wild
type p53), HCT116 (p53 null), lung adenocarcinoma (A549) and
breast adenocarcinoma cells (MCF7) cells using MTT assay with48 h exposure time of the tested compounds, and nutlin-3a was
used as positive control. The results were summarised in Table 2.
In general, all of the synthesised compounds showed a certain
degree of antiproliferative activity against HCT116 (both wild type
p53 and p53 null) cells, and the majority of the target compounds
also presented some antiproliferative activity against the A549 and
MCF7 cell lines. The difference in cytotoxicity of synthesised com-
pounds between tumour cells with wild type p53 (HCT116, A549,
MCF7) may be attributed to: ﬁrstly, as the target, the amounts of
endogenous MDM2 in three cell lines are different, so the cyto-
toxicity of selected compounds to the three cancer cell lines varied;
secondly, the three cell lines are from different tissues; last but not
least, other tumour suppressor genes may be present in A549 and
MCF-7, whichmay lead to reduced activity. Notably, compounds 1b,
3be7b, 1f, 2f, 1h and 2h exhibited superior or comparable activity
against HCT116 (p53þ/þ) to nutlin-3a. In particular, compound 1b
with the most potent inhibitory activity against MDM2ep53
interaction (Ki ¼ 0.093 mM) also showed the best inhibitory activity
against HCT116 (wild type p53). Additionally, all the tested com-
pounds showed relatively lower GI50 values against HCT116 (wild
type p53) compared to HCT116 with p53 deleted, demonstrating
the selectivity of the synthesised compounds over cancer cell lines
with deleted p53. Since compound 1b showed both the highest
binding afﬁnity to MDM2 and the most potent antiproliferative
activity, it was chosen for further mechanism study.
2.7. Western blotting analyses
p53 is activated by the inhibition of the MDM2ep53 interaction,
resulting in the increased expression of wild-type p53 in cells.
Subsequently, p53 activation results in increased levels of p21 and
MDM2 [7]. To further verify the anticancer mechanism of this class
of compounds, western blotting was used to assess the effects of
compound 1b in HCT116 cells. The cells were treated with com-
pound 1b or the positive control nutlin-3a for 48 h. Next, the cells
were lysed and protein extracts were analysed by western blotting
to determine the levels of p53, p21 and MDM2. As shown in Fig. 8,
compound 1b increased the levels of p21, p53 andMDM2 in a dose-
dependent manner in HCT116 cells.
2.8. Cell cycle analysis
To gain a better understanding of the mechanisms that underlie
the antiproliferative activities of this series of compounds, we
investigated the effect of compound 1b on the cell cycle in HCT116
(wild type p53) cells. HCT116 cells were treated with compounds
1b and nutlin-3a for 48 h. The ﬁxed cells were stained with pro-
pidium iodide (PI) and detected using ﬂow cytometry. As shown in
Fig. 9, both compound 1b and nutlin-3a arrested cells in G2/M
phase and induced apoptosis in a dose-dependent manner in
HCT116 cells. Moreover, at the same concentrations, compound 1b
induced more apoptosis than nutlin-3a in HCT116 cells.
2.9. In vivo antitumour activity
To further test the therapeutic potential for the synthesised
compounds, compound 1b was chosen to evaluate its antitumour
activity in the BALB/c mice bearing colon carcinoma cell line CT26
(CT26 rather than HCT116 cell line was chosen to evaluate the
antitumour activity of 1b preliminarily, and the HCT116 xenograft
model will be employed to further investigate the in-vivo anti-
tumour activity of 1b in near future). Before the experiment, the
conﬁguration of double bonds of compound 1b was conﬁrmed
again by NOE experiment, and the isomerisation of the double bond
was not observed.
Table 1
The MDM2 binding afﬁnity of the synthesised compounds.
Compounds R1 R2 R3 R4 R5 Ki (mM)a
1bb H H OMe H OMe 0.093
2bb H Cl OMe H OMe 0.14
1g H Cl Br H OMe 0.23
3b F H OMe H OMe 0.34
4b H H O-n-Pr H O-n-Pr 0.23
5b H Cl O-n-Pr H O-n-Pr 0.28
6b H Cl O-i-Pr H O-i-Pr 0.24
7bb Cl H O-i-Pr H O-i-Pr 0.20
1f H Cl 4-CN-Ph H OMe 0.15
2fb F H 4-CN-Ph H OMe 0.14
3f Cl H 4-CN-Ph OMe H 0.19
1h H Cl 4-Cl-Ph H OMe 0.14
2h H F 4-Cl-Ph H OMe 0.10
Nutlin-3a e e e e e 0.11
a Ki values were determined by ﬂuorescence polarisation assay.
b These compounds were tested as a mixture of isomers, and the ratio of the Z
isomers is less than 5% (Please refer to Supplementary data).
Fig. 7. Proposed binding mode of compound 2h to MDM2 (generated using PyMol).
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tered via an intraperitoneal injection to two groups of BALB/c mice
(10 mice for each group) at doses of 500 mg/kg and 1000 mg/kg,
respectively, to determine themaximum administration dosage. No
death or visible side effects were observed in the 500mg/kg dosage
group over 8 days. However, all of the mice died within 24 h after
the injection of 1000 mg/kg compound 1b. Therefore, the doses
used to evaluate the efﬁcacy of compound 1b were initially set at
50 mg/kg and 100 mg/kg, and oxaliplatin (1.5 mg/kg) was used as
the positive control.
CT26 cancer cell suspensions were implanted subcutaneously
into the right axilla region of the mice, and all the mice were
divided randomly into the following 5 groups (10 mice/group):
compound 1b (50 mg/kg and 100 mg/kg), oxaliplatin (1.5 mg/kg),
vehicle and control groups. The BALB/c mice bearing CT26 colon
carcinoma were treated with compound 1b (100 and 50 mg/kg),
oxaliplatin (1.5 mg/kg) or the vehicle via an intraperitonealFig. 6. Proposed binding mode of compound 1b to MDM2 (generated using PyMol).injection, and the each treatment was given once daily for 10 days.
At the end of the study, all of the mice wereweighed and sacriﬁced,
and the tumourswere excised andweighed for analysis. The ratio of
tumour growth inhibition was calculated using the following for-
mula: (A  B)/A  100% (where A is the average tumour weight of
the control group, and B is the average tumour weight of the
experimental group). The results were summarised in Table 3.
As shown in Table 3, compound 1b effectively inhibited tumour
growth in a dose-dependent manner, with a tumour growth inhi-
bition (TGI) of 18.1% and 32.4% for the low and high-dose group,
respectively. The TGIs observed for compound 1b were inferior to
those for the positive control, oxaliplatin, but were superior to
oxaliplatin in terms of drug tolerance, as determined by the dif-
ference in bodyweight before and after treatment. The bodyweight
of the oxaliplatin group decreased by 4.01 g, whereas it only
decreased by 1.02 and 0.74 g for the high- and low-dose group of
1b, respectively.3. Conclusion
In this study, an integrated virtual screening strategy combining
both pharmacophore- and structure-based approaches identiﬁed a
hit compound with a (E)-3-benzylideneindolin-2-one scaffold as
novel inhibitor of theMDM2ep53 interaction. Further optimisation
led to several derivatives with potent inhibitory activity, among
which 1b showed both the highest binding afﬁnity to MDM2 and
themost potent antiproliferative activity against HCT116 (wild type
p53). Additionally, it possesses a Ki value of 0.093 mM with only 21
non-hydrogen atoms, which means it possesses the highest ligand
efﬁciency value (LE ¼ 1.4 pIC50/N non-hydrogen atoms) [25,26] among
all the synthesised compounds. Consequently, compound 1b rep-
resents promising lead compound for the development of novel
anticancer drugs as MDM2ep53 inhibitors and shows potential for
optimisation to improve its activity without sacriﬁcing its drugg-
ability. The detailed structural optimisation based on its binding
mode to MDM2 proposed in this work is being carried out in our
laboratory.4. Experimental section
4.1. Synthesis and characterisation
1H and 13C NMR spectrawere recorded using TMS as the internal
standard in DMSO-d6 or CDCl3 with a Bruker BioSpin GmbH
Table 2
In vitro antiproliferative activity of the synthesised compounds.
Compounds GI50 (mM)a
HCT116
(p53 þ/þ)
HCT116 (p53 /) A549 MCF7
1b 13.42  2.54 28.14  5.0 52.50  7.70 54.13  7.52
2b 49.19  2.82 126.3  33.94 >100 >100
3b 26.94  3.92 65.55  3.13 >100 88.41  6.44
4b 14.39  1.49 21.32  2.99 42.41  5.60 54.01  2.44
5b 20.96  2.73 26.14  2.67 30.19  6.80 58.42  11.0
6b 29.67  1.58 37.72  1.77 42.58  4.51 55.7  2.32
7b 23.40  0.43 41.97  1.98 30.43  2.62 42.92  1.71
1f 27.10  1.21 124.3  34.66 >100 >100
2f 17.05  1.64 108.9  11.78 >100 >100
3f 48.31  2.76 109.9  4.43 81.58  13.74 >100
1h 32.19  3.82 135.1  49.14 86.67  13.05 >100
2h 15.31  1.18 27.28  1.56 58.82  18.82 >100
1g 53.36  5.97 115.1  49.14 >100 >100
Nutlin-3a 32.11  3.37 55.70  4.66 47.59  4.53 48.74  3.54
a The antiproliferative activity of each compound was tested by MTT assay. The
GI50 values were indicated asmean calculated from three independent experiments.
The drug exposure time was 48 h.
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(MS) were recorded on a Thermo Scientiﬁc LTQ ORBITRAP instru-
ment with an ESI mass selective detector. Melting points (m.p.)
were determined using an SRS-OptiMelt automated melting point
instrument, without correction. Flash column chromatography was
performed with silica gel (200e300 mesh) purchased from Qing-
dao Haiyang Chemical Co. Ltd.
4.1.1. General procedure A for the preparation of 1ae3a
2, 4-Dihydroxybenzaldehyde (200 mmol) and alkylation agent
(440 mmol) were dissolved in 200 ml anhydrous DMF, and potas-
sium carbonate (600 mmol) was added. The mixture was heated at
85 C for 3.5 h, and TLC analysis indicated that the reaction was
complete. The mixture was ﬁltered, and the ﬁltrate was concen-
trated in vacuo. The resulting residue was slowly dissolved in ethyl
acetate, and was rapidly washed with distilled water. The organic
layer was then dried over anhydrousMgSO4 for 2 h and evaporated.
The residue was recrystallised using anhydrous ethanol to give the
corresponding product.
4.1.1.1. 2,4-Dimethoxy-benzaldehyde (1a). 2, 4-
Dihydroxybenzaldehyde and Methyl iodide were dissolved in
DMF, and the mixture was treated with K2CO3 according to general
procedure A to afford the target compound as awhite solid with the
following characteristics: 95% yield; m.p. 69.1e71.2 C; 1H NMR
(600MHz, DMSO-d6): d 10.16 (s, 1H), 7.64 (d, J¼ 8.4 Hz, 1H), 6.66 (d,
J ¼ 2.4 Hz, 1H), 6.62 (dd, J ¼ 2.4 Hz, 8.4 Hz, 1H), 3.89 (s, 3H), 3.86 (s,
3H); MS (ESI): [M þ H]þ m/z 167.1.
4.1.2. 2,4-Dipropoxy-benzaldehyde (2a)
2, 4-Dihydroxybenzaldehyde and 1-bromopropane were dis-
solved in DMF, and the mixture was treated with K2CO3 according
to general procedure A to afford the target compound as a pale
yellow solid with the following characteristics: 90% yield; 1H NMR
(600 MHz, DMSO-d6): d 10.33 (s, 1H), 7.79 (d, J ¼ 9.0 Hz, 1H), 7.12
(dd, J ¼ 1.8 Hz, 9.0 Hz, 1H), 6.42 (d, J ¼ 1.8 Hz, 1H), 3.96e4.01 (m,
4H), 1.80e1.88 (m, 4H), 1.03e1.07 (m, 6H); MS (ESI): [M þ H]þ m/z
223.3.
4.1.2.1. 2, 4-Diisopropoxy-benzaldehyde (3a). 2, 4-
Dihydroxybenzaldehyde and 2-bromopropane were dissolved in
DMF, and the mixture was treated with K2CO3 according to general
procedure A to afford the target compounds as a colourless oil with
the following characteristics: 90% yield; 1H NMR (600 MHz, DMSO-d6): d 10.17 (s, 1H), 7.61 (d, J ¼ 8.4 Hz, 1H), 6.61 (d, J ¼ 2.4 Hz, 1H),
6.56 (dd, J ¼ 2.4 Hz, 8.4 Hz, 1H), 4.72e4.78 (m, 2H), 1.26e1.31 (m,
12H); MS (ESI): [M þ H]þ m/z 223.3.
4.1.3. General procedure B for the preparation of 1be7b, 1fe3f, and
1ge2g
Piperidine (14.4 mL) was slowly added to a suspension of
indolone (70 mmol) and substituted aldehyde (84 mmol) in 80 mL
ethanol. The mixture was heated under reﬂux for 1.5 h, and TLC
analysis indicated when the reaction was complete. After concen-
tration in vacuo, the resulting residue was redissolved in ethyl ac-
etate. Next, the mixture was successively washed with water and
brine. The organic layer was dried over anhydrous MgSO4, ﬁltered
and concentrated, and the resulting residuewas recrystallised from
anhydrous ethanol to give the corresponding product.
4.1.3.1. 3-(2,4-Dimethoxy-benzylidene)-1,3-dihydro-indol-2-one
(1b). 2,4-Dimethoxy-benzaldehyde and 1,3-dihydro-indol-2-one
were dissolved in ethanol, and the mixture was treated with
piperidine, according to general procedure B to afford (1b) as a
yellow solid with the following characteristics: 88% yield; m.p.
206.4e208.1 C; 1H NMR (600 MHz, CDCl3): d 7.95 (s, 1H), 7.73(d,
J¼ 8.4 Hz,1H), 7.66 (d, J¼ 8.4 Hz,1H), 7.55 (br,1H), 7.18 (t, J¼ 8.4 Hz,
1H), 6.85e6.89 (m, 2H), 6.53 (dd, J ¼ 1.8 Hz, 8.4 Hz, 1H), 6.52 (d,
J¼ 1.8 Hz, 1H), 3.90 (s, 3H), 3.87 (s, 3H); 13C NMR (100 MHz, DMSO-
d6): d 168.93(C), 162.70(C), 159.42(C), 142.44(C), 131.71(C),
130.66(C), 129.44(CH), 125.21(CH), 121.95(CH), 121.37(CH),
120.99(CH), 115.31(C), 109.93(CH), 105.32(CH), 98.51(CH),
55.81(CH3), 55.53(CH3); HRMS (ESI): Calculated for [M þ H]þ
(C17H16N1O3), requires m/z 282.1130, found 282.1116.
4.1.3.2. 5-Chloro-3-(2,4-dimethoxy-benzylidene)-1,3-dihydro-indol-
2-one (2b). 2,4-Dimethoxy-benzaldehyde and 5-chloro-1,3-
dihydro-indol-2-one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford (2b) as a yellow solid with the following characteristics: 86%
yield; m.p. 238.3e239.6 C; 1H NMR (600 MHz, CDCl3): d 8.01 (s,
1H), 7.68 (br, 1H), 7.62 (d, J ¼ 1.8 Hz, 1H), 7.16 (dd, J ¼ 1.8 Hz, 8.4 Hz,
1H), 6.80 (d, J ¼ 8.4 Hz, 1H), 6.61 (dd, J¼ 2.4 Hz, 8.4 Hz, 1H), 6.53 (d,
J¼ 2.4 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H); 13C NMR (100 MHz, DMSO-
d6): d 168.56 (C), 163.11 (C), 159.37 (C), 141.16 (CH), 133.65 (C),
130.83 (C), 128.92 (CH), 124.80 (C), 124.23 (CH), 122.80 (C), 121.21
(CH), 114.92 (CH), 111.30 (CH), 105.54 (C), 98.62 (CH), 55.80 (CH3),
55.65 (CH3); HRMS (ESI): Calculated for [M þ H]þ (C17H15Cl1N1O3),
requires m/z 316.0741, found 316.0738.
4.1.3.3. 3-(2,4-Dimethoxy-benzylidene)-6-ﬂuoro-1,3-dihydro-indol-
2-one (3b). 2,4-Dimethoxy-benzaldehyde and 6-ﬂuoro-1,3-
dihydro-indol-2-one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford 3b as a yellow solid with the following characteristics: 86%
yield; m.p. 226.3e227.6 C; 1H NMR (600 MHz, CDCl3): d 8.01 (s,
1H), 7.86 (br, 1H), 7.67 (d, J¼ 9.0 Hz, 1H), 7.37 (dd, J¼ 2.4 Hz, 9.0 Hz,
1H), 6.91 (d, J ¼ 2.4 Hz, 1H), 6.79 (d, J ¼ 8.4 Hz, 1H), 6.59 (dd,
J ¼ 2.4 Hz, 8.4 Hz, 1H), 6.52 (d, J ¼ 2.4 Hz, 1H), 3.90 (s, 3H), 3.87 (s,
3H); 13C NMR (100 MHz, DMSO-d6): d 168.91(C), 163.07(C),
159.55(C), 158.34(C), 138.76(C), 133.38(C), 130.75(C), 124.92(CH),
122.36(CH), 116.06(CH), 114.92(C), 110.60(CH), 105.50(CH),
98.64(CH), 97.61(CH), 55.87(CH3), 55.66(CH3); HRMS (ESI): Calcu-
lated for [M þ H]þ (C17H15F1N1O3), requires m/z 300.0958, found
300.1036.
4.1.3.4. 3-(2,4-Dipropoxy-benzylidene)-1,3-dihydro-indol-2-one
(4b). 2,4-Dipropoxy-benzaldehyde and 1,3-dihydro-indol-2-one
were dissolved in ethanol, and the mixture was treated with
Fig. 8. The activation of the p53 pathway in HCT116 cells by compounds 1b and nutlin-
3a (western blotting).
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solid with the following characteristics: 86% yield; m.p. 162.3e
163.4 C; 1H NMR (600 MHz, CDCl3): d 7.99 (s, 1H), 7.72 (d,
J¼ 7.8 Hz,1H), 7.69 (d, J¼ 7.8 Hz,1H),7.18 (d, J¼ 8.4 Hz,1H), 6.87 (m,
2H), 6.54 (dd, J ¼ 2.4 Hz, 8.4 Hz, 1H), 6.50 (d, J ¼ 2.4 Hz, 1H), 4.00 (t,
J ¼ 6.6 Hz, 2H), 3.97 (t, J ¼ 6.6 Hz, 2H), 1.87e1.81 (m, 4H), 1.75 (t,
J ¼ 7.2 Hz, 3H), 1.02 (t, J ¼ 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO-
d6): d 168.98(C), 162.09(C), 158.85(C), 142.36(C), 131.79(C),
130.73(C), 129.35(CH), 125.04(CH), 121.93(CH), 121.44(CH),
120.94(CH), 115.34(C), 109.88(CH), 105.75(CH), 99.49(CH),
69.53(CH3), 69.30(CH2), 22.03(CH2), 21.96(CH2), 10.44(CH3); HRMS
(ESI): Calculated for [M þ H]þ (C21H23N1O3) requires m/z 338.1756,
found 338.1761.4.1.3.5. 5-Chloro-3-(2,4-dipropoxy-benzylidene)-1,3-dihydro-indol-
2-one (5b). 2,4-Dipropoxy-benzaldehyde and 5-chloro-1,3-
dihydro-indol-2-one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford 5b as a yellow solid with the following characteristics: 86%
yield; m.p. 171.1e172.2 C; 1H NMR (600MHz, CDCl3): d 8.03 (s, 1H),
7.65 (d, J ¼ 8.4 Hz, 1H), 7.63 (d, J ¼ 2.4 Hz, 1H), 7.15 (d, J ¼ 2.4 Hz,
8.4 Hz, 1H), 6.82(d, J ¼ 8.4 Hz, 1H) 6.58 (dd, J ¼ 2.4 Hz, 8.4 Hz, 1H),
6.51 (d, J¼ 2.4 Hz, 1H), 3.97e4.02 (m, 4H), 1.79e1.88 (m, 4H), 1.10 (t,
J ¼ 7.8 Hz, 3H), 1.02 (t, J ¼ 7.2 Hz, 3H). 13C NMR (100 MHz, DMSO-Fig. 9. G2/M phase arrest and the induction of apoptosis in HCd6): d 168.69(C), 162.55(C), 159.00(C), 141.10(C), 133.70(C),
130.95(C), 128.80(C), 124.81(CH), 124.20(CH), 123.19(CH),
121.51(CH), 114.94(CH), 111.22(CH), 105.93(C), 99.57(CH),
69.61(CH2), 69.40(CH2), 22.05(CH2), 21.94(CH2), 10.44(CH3); HRMS
(ESI): Calculated for [M þ H]þ (C21H23Cl1N1O3), requires m/z
372.1367, found 372.1354.4.1.3.6. 5-Chloro-3-(2,4-diisopropoxy-benzylidene)-1,3-dihydro-
indol-2-one (6b). 2,4-Dipropoxy-benzaldehyde and 5-chloro-1,3-
dihydro-indol-2-one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford 6b as a yellow solid with the following characteristics: 86%
yield;m.p.170.8e172.1 C; 1H NMR (600MHz, CDCl3): d 8.05 (s,1H),
8.01 (s, 1H), 7.66 (d, J ¼ 8.4 Hz, 1H), 7.44 (d, J ¼ 2.4 Hz, 1H), 7.13 (dd,
J ¼ 2.4 Hz, 8.4 Hz, 1H), 6.76 (d, J ¼ 8.4 Hz, 1H) 6.52 (dd, J ¼ 2.4 Hz,
8.4 Hz, 1H), 6.42 (d, J ¼ 2.4 Hz, 1H), 4.58e4.67 (m, 2H), 1.40 (d,
J ¼ 6.0 Hz, 6H), 1.36 (d, J ¼ 6.6 Hz, 6H); 13C NMR: (100 MHz, DMSO-
d6): d 168.75(C), 161.34(C), 158.09(C), 141.07(C), 134.14(C), 131.09(C),
128.73(C), 124.76(CH), 123.94(CH), 123.18(CH), 121.48(CH),
115.42(CH), 111.20(C), 106.80(CH), 101.46(CH), 70.41(CH),
69.67(CH), 21.83(CH3); HRMS (ESI): Calculated for [M þ H]þ
(C21H23Cl1N1O3) requires m/z 372.1367, found 372.1385.4.1.3.7. 6-Chloro-3-(2,4-diisopropoxy-benzylidene)-1,3-dihydro-
indol-2-one (7b). 2,4-Diisopropoxy-benzaldehyde and 6-chloro-
1,3-dihydro-indol-2-one were dissolved in ethanol, and the
mixturewas treated by piperidine according to general procedure B
to afford 7b as a yellow solid with the following characteristics: 86%
yield; m.p. 173.1e173.9 C; 1H NMR (600MHz, CDCl3): d 7.91 (s, 1H),
7.62 (d, J ¼ 8.4 Hz, 1H), 7.52 (d, J ¼ 8.4 Hz, 1H), 6.90 (dd, J ¼ 2.4 Hz,
8.4 Hz, 1H), 6.85 (d, J ¼ 8.4 Hz, 1H), 6.78 (dd, J ¼ 2.4 Hz, 8.4 Hz, 1H),
6.58 (d, J ¼ 2.4 Hz, 1H), 4.71e4.75 (m, 2H), 1.33 (d, J ¼ 6.0 Hz, 6H),
1.28 (d, J ¼ 6.6 Hz, 6H); 13C NMR (100 MHz, DMSO-d6): d 169.01(C),
161.17(C), 158.08(C), 143.63(C), 133.13(C), 131.01(C), 123.59(C),
123.21(CH), 120.71(CH), 120.42(CH), 115.60(C), 109.80(CH),
106.83(CH), 101.47(CH), 70.35(CH), 69.58(CH), 21.48(CH3); HRMS
(ESI): Calculated for [M þ H]þ (C21H23Cl1N1O3) requires m/z
372.1367, found 372.1352.T116 cells after treatment with compound 1b or nutlin-3a.
Table 3
In vivo tumour growth inhibition in response to compound 1b and oxaliplatin.
Group Dosage
(mg/kg)
No. of mice Body weight (g) Tumour
weighta (g)
TGI %
Begin End Begin End
Control e 10 10 19.51 20.02 1.93  0.39 e
Oxaliplatin 1.5 10 10 19.40 15.39 0.92  0.14** 52.3
Vehicle e 10 10 19.77 19.45 1.85  0.24 4.7
1b 100 10 10 19.93 18.91 1.30  0.13** 32.4
50 10 10 19.69 18.95 1.58  0.27* 18.1
a Student’s t-test was used to compare the means of two groups, and analysis of
variance was used to compare the means of multiple groups. For all of the differ-
ences, a P value of less than 0.05 was considered to be statistically
signiﬁcant.**P < 0.01, *P < 0.05.
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methoxy-biphenyl -4-carbonitrile (1f).
20-Formyl-50-methoxy-biphenyl-4-carbonitrile and 6-chloro-1,3-
dihydro-indol-2- one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford 1f as a yellow solid with the following characteristics: 86%
yield; m.p.>280 C; 1H NMR (600MHz, CDCl3): d 7.81 (d, J¼ 8.4 Hz,
2H), 7.70 (d, J ¼ 8.4 Hz, 2H), 7.60 (s, 1H), 7.59 (d, J ¼ 1.8 Hz, 1H), 7.46
(d, J ¼ 8.4 Hz, 1H), 7.21 (dd, J ¼ 1.8 Hz, 8.4 Hz, 1H), 7.07 (dd,
J¼ 2.4 Hz, 8.4 Hz,1H), 7.01 (d, J¼ 2.4 Hz,1H), 6.82 (d, J¼ 8.4 Hz,1H),
3.95 (s, 3H); 13C NMR: (100 MHz, DMSO-d6): d 168.80(C), 168.16(C),
144.10(C), 142.23(C), 141.50(C), 136.56(C), 132.35(C), 131.19(CH),
130.84(CH), 130.52(CH), 129.39(CH), 128.19(C), 126.21(C),
124.93(CH), 124.30(CH), 122.85(CH), 121.82(CH), 118.56(CH),
115.40(C), 114.44(CH), 111.45(CH), 110.80(CH), 55.69(CH3); HRMS
(ESI): Calculated for [M þ H]þ (C23H15Cl1N2O2) requires m/z
387.0900, found 387.0895.4.1.3.9. 20-(6-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-50-
methoxy-biphenyl -4-carbonitrile (2f).
20-Formyl-50-methoxy-biphenyl-4-carbonitrile and 6-ﬂuoro-1,3-
dihydroeindol -2-one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford 2f as a yellow solid with the following characteristics: 86%
yield; m.p. >280 C; 1H NMR (600 MHz, CDCl3): d 7.91 (s, 1H), 7.70
(d, J ¼ 8.4 Hz, 2H), 7.60 (d, J ¼ 2.4 Hz, 1H), 7.51 (d, J ¼ 8.4 Hz, 1H),
7.46 (d, J ¼ 8.4 Hz, 2H), 7.21 (dd, J ¼ 2.4 Hz, 8.4 Hz, 1H), 7.07 (dd,
J¼ 1.8 Hz, 8.4 Hz,1H), 7.01 (d, J¼ 2.4 Hz,1H), 6.82 (d, J¼ 8.4 Hz,1H),
3.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 168.43(C), 160.71(C),
158.39(C), 155.75(C), 144.12(C), 142.14(C), 139.07(C), 136.34(CH),
132.36(CH), 131.14(CH), 130.51(CH), 126.79(CH), 124.27(CH),
122.13(C), 118.66(CH), 116.30(CH), 116.07(C), 115.46(CH),
114.41(CH), 110.79(C), 109.53(CH), 109.26(CH), 55.68(CH3); HRMS
(ESI): Calculated for [M þ H]þ (C23H15F1N2O2) requires m/z
371.1196, found 371.1201.4.1.3.10. 20-(6-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-60-
methoxy-biphenyl- 4-carbonitrile (3f).
20-Formyl-60-methoxy-biphenyl-4-carbonitrile and 6-chloro-1,3-
dihydroeindol -2-one were dissolved in ethanol, and the mixture
was treated with piperidine according to general procedure B to
afford 3f as a yellow solid with the following characteristics: 86%
yield; m.p. >280 C; 1H NMR (400 MHz, DMSO-d6): d 10.72 (s, 1H),
7.94 (d, J ¼ 8.0 Hz, 2H), 7.83 (d, J ¼ 8.0 Hz, 2H), 7.61 (d, J ¼ 8.0 Hz,
1H), 7.42 (d, J ¼ 2.0 Hz, 1H), 7.29e7.32 (m, 1H), 7.23 (dd, J ¼ 2.0 Hz,
8.0 Hz, 1H), 7.17e7.19 (m, 1H), 6.90 (d, J ¼ 8.0 Hz, 1H), 3.92 (s, 3H);
13C NMR: (100 MHz, DMSO-d6): d 168.61(C), 166.88(C), 143.13(C),
141.50(C), 139.41(C), 136.52(C), 135.32(C), 135.07(C), 129.46(CH),
128.51(CH), 128.07(C), 124.50(CH), 124.43(CH), 122.62(CH),
122.31(CH), 121.64(CH), 113.90(C), 113.52(CH), 112.53(CH),110.77(CH), 110.09(CH), 57.04(CH). HRMS (ESI): Calculated for
[M þ H]þ (C23H15Cl1N2O2) requires m/z 387.0900, found 387.0890.
4.1.3.11. 3-(2-Bromo-4-methoxy-benzylidene)-5-chloro-1,3-dihydro-
indol-2-one (1g). 2-Bromo-4-methoxy-benzaldehyde and 6-
chloro-1,3-dihydroeindol-2-one were dissolved in ethanol, and
the mixture was treated with piperidine according to general
procedure B to afford 1g as a yellow solid with the following
characteristics: 74% yield; m.p. 247.5e249.2 C; 1H NMR (600 MHz,
CDCl3): d 7.82 (s, 1H), 7.70 (br, 1H), 7.65 (d, J ¼ 8.4 Hz, 1H), 7.41 (d,
J ¼ 2.4 Hz, 1H), 7.25e7.26 (m, 1H), 7.18 (d, J ¼ 2.4 Hz, 1H), 6.97 (dd,
J ¼ 2.4 Hz, 8.4 Hz, 1H), 6.81 (d, J ¼ 8.4 Hz, 1H), 3.89 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 168.07(C), 161.26(C), 141.73(C), 135.65(C),
131.40(C),129.83(C),126.95(C),126.02(CH),125.05(CH),124.93(CH),
122.36(CH), 121.82(C), 118.22(CH), 114.23(CH), 111.66(CH),
56.02(CH3); HRMS (ESI): Calculated for [M þ H]þ
(C16H12Br1Cl1N1O2) requires m/z 363.9740, found 363.9725.
4.1.3.12. 3-(2-Bromo-4-methoxy-benzylidene)-5-ﬂuoro-1,3-dihydro-
indol-2-one (2g). 2-Bromo-4-methoxy-benzaldehyde and 5-
ﬂuoro-1,3-dihydro-indol-2-one were dissolved in ethanol, and the
mixture was treated with piperidine according to general proce-
dure B to afford 2g as a yellow solid with the following character-
istics: 92% yield; m.p. 273.7e274.2 C; 1H NMR (600 MHz, CDCl3):
d 7.84 (s, 1H), 7.65 (d, J ¼ 8.4 Hz, 1H), 7.41 (d, J ¼ 1.8 Hz, 1H), 7.30 (d,
J ¼ 8.4 Hz, 1H), 7.19 (dd, J ¼ 1.8 Hz, 8.4 Hz, 1H), 6.97 (dd, J ¼ 2.4 Hz,
8.4 Hz, 1H), 6.80 (d, J¼ 2.4 Hz, 1H), 3.88 (s, 3H); 13C NMR (100 MHz,
DMSO-d6): d 168.61(C), 156.60(C), 144.91(C), 136.52(C), 135.07(C),
129.46(C), 128.51(C), 124.50(CH), 124.43(CH), 122.62(CH),
122.31(CH), 121.64(C), 113.52(CH), 112.53(CH), 110.09(CH),
57.04(CH3); MS (ESI): [M þ H]þ m/z 350.0.
4.1.4. General procedure C of preparation of 1d and 2d
Substituted bromobenzene (80 mmol), bis(pinacolato)diboron
(120 mmol), potassium acetate (160 mmol) and triphenylphos-
phine palladium (8 mmol) were dissolved in anhydrous DMSO
under N2 protection. The mixture was heated to 85 C for 4 h, and
TLC analysis indicated when the reaction was complete. Next,
distilled water was added. The mixture was extracted by ethyl ac-
etate, dried over anhydrous MgSO4 for 2 h and evaporated. The
residue was chromatographed on silica gel and eluted with Petro-
leum ether/Ethyl acetate to produce 1d and 2d.
4.1.4.1. 2-(4-Chloro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxabor-
olane (1d). 1-Bromo-4-chloro-benzene was treated with bis(pina-
colato)diboron according to general procedure C to afford 1d as a
white solid with the following characteristics: 60% yield; m.p.
50.1e51.1 C; 1H NMR (600 MHz, DMSO-d6): d 7.68 (d, J ¼ 8.4 Hz,
2H), 7.46 (d, J ¼ 8.4 Hz, 2H), 1.28 (s, 12H); MS (ESI): [M þ H]þ m/z
239.1.
4.1.4.2. 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile
(2d). The 4-bromo-benzonitrile was treated with bis(pinacolato)
diboron according to general procedure C to afford 2d as a white
solid with the following characteristics: 74% yield; m.p. 93.5e
94.3 C; 1H NMR (400 MHz, DMSO-d6): d 7.66 (d, J ¼ 8.4 Hz, 2H),
7.43 (d, J ¼ 8.4 Hz, 2H), 1.30 (s, 12H); MS (ESI): [M þ H]þ m/z 230.1.
4.1.4.3. 20-Formyl-50-methoxy-biphenyl-4-carbonitrile (1e).
Caesium carbonate (350 mmol) was added to a stirred suspension
of 1d (150 mmol) and 2-bromo-4-methoxyebenzaldehyde
(150 mmol) in 100 mL DMF, followed by the addition of triphe-
nylphosphine palladium (15 mmol). The reaction was heated at
120 C for 4 h and then allowed to cool to room temperature. The
organic solvent was removed in vacuo and diluted in ethyl acetate.
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organic layer was then dried over anhydrous MgSO4. The organic
solvent was removed by rotary evaporation, and the residue was
puriﬁed using column chromatography with petroleum ether/ethyl
acetate to afford 1e with the following characteristics: 70% yield;
m.p.138.7e139.9 C; 1H NMR (600MHz, CDCl3): d 10.21 (s, 1H), 7.83
(d, J ¼ 9.0 Hz, 2H), 7.50 (d, J ¼ 9.0 Hz, 2H), 7.38 (d, J ¼ 2.4 Hz, 1H),
6.77 (dd, J¼ 2.4 Hz, 9.0 Hz, 1H), 6.64 (d, J¼ 9.0 Hz, 1H), 3.84 (s, 3H);
MS (ESI): [M þ H]þ m/z 238.1.
4.1.4.4. 20-Formyl-60-methoxy-biphenyl-4-carbonitrile (2e).
Caesium carbonate (350 mmol) was added to a stirred suspension
of 1d (150 mmol) and 2-bromo-3-methoxy-benzaldehyde
(150 mmol) in 100 mL DMF, followed by the addition of triphe-
nylphosphine palladium (15 mmol). The reaction was heated at
120 C for 5.5 h and then allowed to cool to room temperature. The
organic solvent was removed in vacuo and diluted in ethyl acetate.
The entire mixture was washed with ice water (200 mL). The
organic layer was then dried over anhydrous MgSO4. The organic
solvent was removed by rotary evaporation, and the residue was
puriﬁed using column chromatography with petroleum ether/ethyl
acetate to afford 1e with the following characteristics: 55% yield;
m.p. 132.7e134.2 C; 1H NMR (600 MHz, DMSO-d6): d 9.61 (s, 1H),
7.90 (d, J¼ 7.8 Hz, 2H), 7.60 (t, J¼ 7.8 Hz,1H), 7.52 (d, J¼ 7.8 Hz, 2H),
7.46 (d, J ¼ 7.8 Hz, 2H), 3.75 (s, 3H); MS (ESI): [M þ H]þ m/z 238.1.
4.1.5. General procedure C for the preparation of 1h and 2h
Caesium carbonate (300 mmol) was added to a stirred suspen-
sion of 1g or 2g (100 mmol) and 1d in 100 mL DMF, followed by the
addition of triphenylphosphine palladium (10 mmol). The reaction
was heated at 120 C for 4 h and then allowed to cool to room
temperature. The organic solvent was removed in vacuo and diluted
in ethyl acetate. The entire mixture was washed with ice water
(200 mL). The organic layer was then dried over anhydrous MgSO4.
The organic solvent was removed by rotary evaporation, and the
residue was puriﬁed using column chromatography with petro-
leum ether/ethyl acetate to produce 1h and 2h.
4.1.5.1. 5-Chloro-3-(40-chloro-5-methoxy-biphenyl-2-ylmethylene)-
1,3-dihydro-indol-2-one (1h). 1g and 1d were dissolved in DMF,
according to general procedure C to afford compound 1h with the
following characteristics: 54% yield; m.p. 202.6e204.1 C; 1H NMR
(600 MHz, CDCl3): d 7.80 (d, J ¼ 8.4 Hz, 1H), 7.69 (d, J ¼ 8.4 Hz, 1H),
7.60 (d, J ¼ 3.0 Hz, 1H), 7.45 (d, J ¼ 8.4 Hz, 2H), 7.20e7.22 (m, 1H),
7.07 (d, J ¼ 3.0 Hz, 1H), 7.01 (dd, J ¼ 3.0 Hz, 9.0 Hz, 1H), 6.81 (d,
J ¼ 9.0 Hz, 1H), 3.95 (s, 3H); 13C NMR (100 MHz, DMSO-d6):
d 168.08(C), 160.74(C), 144.05(C), 142.15(C), 141.46(C), 136.47(C),
132.26(C), 131.11(CH), 130.45(CH), 129.32(C), 126.20(C), 124.89(CH),
124.27(CH), 122.80(CH), 121.78(CH), 118.57(CH), 115.35(CH),
114.38(CH), 111.38(CH), 110.75(CH), 55.62(CH3); HRMS (ESI):
Calculated for [M þ H]þ (C22H15N1O2Cl2) requires m/z 395.0480,
found 395.0429.
4.1.5.2. 3-(40-Chloro-5-methoxy-biphenyl-2-ylmethylene)-5-ﬂuoro-
1,3-dihydro-indol-2-one (2h). 2g and 1d were dissolved in DMF
according to general procedure C to afford compound (2h)with the
following characteristics: 65% yield; m.p. 268.2e269.7 C; 1H NMR
(600 MHz, CDCl3): d 7.79 (s, 1H), 7. 78 (d, J ¼ 8.4 Hz, 2H), 7.37 (d,
J¼ 8.4 Hz, 2H), 7.27 (d, J¼ 9.0 Hz,1H), 7.26 (s, 1H) 7.02 (d, J¼ 9.0 Hz,
1H), 6.93 (d, J ¼ 8.4 Hz, 1H), 6.92 (d, J ¼ 2.4 Hz, 1H), 6.82 (dd,
J ¼ 2.4 Hz, 8.4 Hz, 1H) 3.92 (s, 3H); 13C NMR (100 MHz, DMSO-d6):
d 168.09(C), 160.74(C), 144.06(C), 142.16(C), 141.47(C), 136.47(C),
132.26(C), 131.11(CH), 130.44(CH), 129.32(CH), 126.21(C),
124.88(CH), 124.28(CH), 122.80(C), 121.79(CH), 118.58(CH),
115.36(CH), 114.38(CH), 111.38(CH), 110.76(CH), 55.63(CH3); HRMS(ESI): Calculated for [M þ H]þ (C22H15N1 O2Cl1F1) requires m/z
380.0775, found 380.0849.
4.2. Biological assay
A549, HCT116 and MCF7 cell lines were purchased from the
American Type Culture Collection. MDM2 binding domain (1e118)
was purchased from Creative Biomart, and the PMDM-F was ob-
tained from AnaSpec Inc. The positive control drug, nutlin-3a, was
purchased from Haoyuan Chempress Shanghai. All the tested
compounds were dissolved in DMSO to 100 mM stock solutions,
and they were further diluted with culture medium prior to use.
4.2.1. MTT assay
The cells were seeded into a 96-well plate at a density of 5000
(100 mL) per well for 24 h, followed by drug treatment (100 mL) for
48 h. Next, 20 mL of 5mg/mlMTTwas added to themedium, and the
cells were incubated for 4 h at 37 C and 5% CO2. After removing the
culture medium, 150 mL of DMSO was added. The plates were read
using an enzyme-linked immunosorbent assay plate reader at
570 nm. The viability of untreated cells was set as 100%, and the
viability in the other groups was calculated by comparing the op-
tical density reading with the control. The GI50 values were calcu-
lated using nonlinear regression analysis. The assays were repeated
three times.
4.2.2. MDM2 binding assay
The dose-dependent binding experiments were carried out with
serial dilution in DMSO of compounds. A 3 mL sample of the tested
compounds and preincubated (for 30 min) MDM2 binding domain
(1e118) (30 nM) and PMDM-F peptide (10 nM) in the assay buffer
(100 mM potassium phosphate, pH 7.5; 100 mg/mL bovine gamma
globulin; 0.02% sodium azide) was added into black 96-well
microplates with F-bottom and chimney wells (Corning) to pro-
duce a ﬁnal volume of 115 mL. For each assay, the controls included
the MDM2 binding domain and PMDM-F. The polarisation values
were measured at room temperature using Biotek Synergy H2 with
a 485 nm excitation ﬁlter, a 528 nm static and polarised ﬁlter. The Ki
value was calculated according to a reported method [27].
4.2.3. Western blotting
HCT116 cells (wild type p53) were treated with various con-
centrations of the indicated compound for 48 h. Next, the cells were
harvested by centrifugation at 1000 g for 5 min. The cell pellets
were washed with PBS, resuspended in lysis buffer (150 mM NaCl,
50 mM Tris (pH 8.0), 0.02% NaN3, 0.01% PMSF, 0.2% Aprotinin, and
1% TritonX-100, supplemented with protease inhibitor cocktail
(Thermo Scientiﬁc)), and centrifuged at 12,000 g for 10 min. The
total protein concentration was determined using the Bio-Rad
protein assay. The proteins were resolved by SDS-PAGE and trans-
ferred to a polyvinylidene ﬂuoride membrane. After blocking with
5% non-fat milk in blocking buffer (PBS containing 0.1% Tween 20,
pH 7.5), the membrane was incubated with the indicated primary
antibody for 2 h at room temperature and then incubated with the
appropriate peroxidase-conjugated secondary antibody. The
immunoreactive bands were visualised using the ECL Plus Western
Blotting Detection System (Piscataway, New Jersey, USA). Beta-actin
was used as a loading control.
4.2.4. Cell cycle analysis
HCT116 cells were seeded at 2  105 cells/well in 6-well plates
and cultured for 48 h. Next, the cells were incubated with the test
compounds for 48 h. The cells were then treated with cold PBS.
After harvest, the cells were ﬁxed in 70% ice-cold ethanol overnight.
Subsequently, the cells were centrifuged (1200 rpm for 5 min), the
G.-h. Zheng et al. / European Journal of Medicinal Chemistry 81 (2014) 277e288 287supernatant was discarded and the pellet was treated with RNase A
(100 mg/ml) for 30 min at room temperature. The cells were stained
using propidium iodide at a ﬁnal concentration of 50 mg/mL. The
stained cells were then analysed for cell cycle distribution using
ﬂow cytometry (BECKMAN), and the changes in the cell cycle
proﬁles was analysed using CELL QUEST PRO.
4.3. In vivo antitumour assay
Oxaliplatinwas obtained from the Cancer Institute and Hospital,
Chinese Academy of Medical Sciences (CAMS). BALB/mice were
obtained from the Institute for Experimental Animals, Chinese
Academy of Medical Sciences & Peking Union Medical College, and
animal care was in compliance with the regulations issued by the
Beijing Committee of Laboratory Animals.
4.3.1. Exploration of maximum administration dosage
BALB/c mice were randomised into two groups (10 mice/group),
and each group was administered compound 1b dissolved in 10%
DMSO via an intraperitoneal injection at doses of 500 mg/kg and
1000 mg/kg, respectively. The mice were monitored for visible
signs of toxicity for 8 days.
4.3.2. Antitumour efﬁciency assay
CT26 cancer cell suspensions were subcutaneously implanted
into the right axilla region of the mice. Next, the BALB/c mice were
randomised into 5 groups (10 mice/group) that received the
following treatments: blank control, 100 mg/kg or 50 mg/kg of 1b,
1.5 mg/kg of the positive control oxaliplatin or vehicle. The treat-
ment was initiated 24 h after tumour implantation, and the treat-
ments were administered once per day for ten days. Twenty-four
hours after the ﬁnal administration, the mice were weighed and
sacriﬁced, and the tumours were excised, weighed and recorded for
analysis.
4.4. Computational protocol
The pharmacophore was generated manually in Discovery stu-
dio 3.0 using the crystal structure of Pip-1 complexed with MDM2
(PDB ID: 2 LZG) as reference and was validated by calculating the
ROC curve of the test set. Virtual screening was performed in the
“screen library” module, the “conformation generation” was set to
“fast”, and the other parameters were set as default. The obtained
compounds were further ﬁltered by the “Rule of ﬁve”, and they
were then subjected to docking analysis using sybyl 7.3. The crystal
structure with PDB ID 3LBL was prepared in sybyl 7.3 by removing
the ligand and the water molecules and adding hydrogen atoms.
The docking parameters were all set as default. After the docking
was completed, a visual inspection for potential hit compoundswas
performed to identify the top 200 compounds ranked by docking
score.
The binding mode for compounds 4b,1b and 2hwere generated
by molecular docking using Autodock 4.2. The receptor and the li-
gands were prepared using AutoDockTools and saved as pdbqt ﬁles.
The centre of grid box was set to “33.547, 16.037, 51.308”, and
the number of points in the x, y and z dimensions were 46, 48 and
44, respectively. All the parameters for docking were set as default.
After docking was completed, PyMol was used to analyse the
docking poses and generate publication quality ﬁgures.
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